Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Lung Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasms 5Neoplasm Metastasis 4Colorectal Neoplasms 4Colonic Neoplasms 3Advanced Solid Tumors 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Pancreatic Neoplasms 2Non-squamous Non-small Cell Lung Cancer 2Mesothelioma 2Meningeal Carcinomatosis 2Melanoma 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pathologic Processes 1Pathologic Complete Response 1Ovarian Neoplasms 1

Interventions

durvalumab 2Tretinoin 2Paclitaxel 2Carboplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1sarilumab 1pexidartinib 1pertuzumab 1pembrolizumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1dostarlimab 1cemiplimab 1abemaciclib 1Trastuzumab 1Standard of Care 1STA 9090 1SGN-LIV1A 1Pemetrexed 1MK 2206 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Pemetrexed × 30 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡